Trial Profile
Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir; Ledipasvir/sofosbuvir; Ombitasvir/paritaprevir/ritonavir; Ribavirin; Sofosbuvir; Sofosbuvir/velpatasvir
- Indications Hepatitis C
- Focus Adverse reactions
- 20 Sep 2018 Status changed from recruiting to completed.
- 15 Mar 2017 Planned number of patients changed from 11 to 111.
- 01 Dec 2016 Planned number of patients changed from 222 to 11.